Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment

Artificial Organs

Volumn 20, Issue 7, 1996, Pages 767-776

  Fukutomi, Masaaki ^a   Kobayashi, Shuichi ^a   Niwaya, Kazuo ^a   Hamada, Yoshihiro ^a   Kitamura, Soichiro ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Biocompatibility; Cardiopulmonary bypass; Complement activation; Granulocyte activation; Heparin coating; Platelet activation

Indexed keywords

CHEMICAL ACTIVATION; PLATELETS; POLYSACCHARIDES; URANIUM COMPOUNDS;

2-GROUP; BLOOD LOSS; BYPASS SYSTEMS; CARDIOPULMONARY BYPASS; CARDIOPULMONARY BYPASS CIRCUIT; COMPLEMENT ACTIVATIONS; CORONARY ARTERY BYPASS SURGERY; GRANULOCYTE ACTIVATION; HEPARIN COATINGS; PLATELET ACTIVATION;

BIOCOMPATIBILITY;

HEPARIN; PROTAMINE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; FEMALE; GRANULOCYTE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE;

EID: 0030036035     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1996.tb04538.x     Document Type: Article

References (25)

1. Royston D. Blood cell activation in cardiopulmonary bypass. Semin Thorac Cardiovasc Surg 1990;2:341-57.
2. 2 levels during cardiopulmonary bypass. Circulation 1980;61:808-14.
3. Harker LA, Malpass TW, Branson HE, Hessel EA II, Slighter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha granules release. Blood 1980;56:824-34.
4. Mammen EF, Koets MH, Wolk LW, Brown JM, Murano G. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemostat 1985;11:281-92.
5. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57.
6. Bosner RS, Dave J, Gademsetty M, Carter P, Davies E, Taylor P, Gaya H, Lennox SC, Vergani D. Complement activation before, during and after cardiopulmonary bypass. Eur J Cardiothorac Surg 1990;4:291-6.
7. Bando K, Pillai R, Cameron DE, Brawn JD, Winkelstein JA, Hutchins GM, Reitz BA, Baumgartner WA. Leukocyte depletion ameliorates free radical mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99:873-7.
8. Nilson L, Storm KE, Thelin S. Heparin-coated equipment reduces complements activation during cardiopulmonary bypass in the pig. Artif Organs 1991;15:90-5.
9. Videm V, Mollnes TE, Garred P, Svennevig JL. Biocompatibility of extracorporeal circulation: In vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991;101:654-60.
10. Von Segsser LK, Weiss BM, Garcia E, von Felten A, Tulina MI. Reduction and elimination of systemic heparinization during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;103:790-8.
11. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes TE. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operation. J Thorac Cardiovasc Surg 1992;103:806-13.
12. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-23.
13. Hatori N, Yoshizu H, Haga Y, Kusami Y, Takeshima S, Segawa D, Tanaka S. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. Artif Organs 1994;18:904-10.
14. Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, Wenger RK, Rucinski B, Niewiarowski S, Edmunds LH Jr., Colman RW. Human neutrophil degranulation during extracorporeal circulation. Blood 1987;59:324-30.
15. Horl WH, Feinstein El, Wanner C, Frischmuth N, Gosel A, Massry SG. Plasma levels of main granulocyte components during hemodialysis: Comparison of new and reused dialyzers. Am J Nephrol 1990;10:53-7.
16. Vhelvart M, Fehr K. Degradation in vivo of articular cartilage in rheumatoid arthritis and juvenile chronic arthritis by cathepsin G and elastase from polymorphonuclear leukocytes. Rheumatol Int 1987;7:195-202.
17. Yokota J, Minei JP, Fantini GA, Shires GT. Role of leukocytes in reperfusion injury of skeletal muscle after partial ischemia. Am J Physiol 1989;257:H1068-75.
18. Weiss SJ. Mechanisms of disease: Tissue destruction by neutrophil. N Eng J Med 1989;320:365-76.
19. Ward PA, Till GO, Kunkel R, Beauchamp C. Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invent 1983;72:789-801.
20. Mollnes TE, Videm V, Gotze O, Harboe M, Oppermann M, Formation of C5a during cardiopulmonary bypass: Inhibition by precoating with heparin. Ann Thorac Surg 1991;52: 92-7.
21. Chenoweth DE, Hugli TE. Demonstration of specific C5a receptors on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978;75:3943-7.
22. Salama A, Hugo F, Heinrich D, Hoge R, Muller R, Kiefel V, Mueller-Eckhardt C, Bhakdi S. Deposition of terminal C5b-9 complement complex on erythrocytes and leukocytes during cardiopulmonary bypass. N Eng J Med 1988;318:408-14.
23. Fish KJ, Sarnquist FH, van Steennis C, Mitchell RS, Hilberman M, Jaimieson SW, Linet OI, Miller DC. A prospective randomized study of the effect of prostacyclin on platelets and blood loss during coronary bypass operation. J Thorac Cardiovasc Surg 1986;91:436-42.
24. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958-67.
25. von Segesser LK, Garcia E, Turina MI. Low-dose heparin versus full-dose heparin with high-dose aprotinin during cardiopulmonary bypass: A preliminary report. Texas Heart Institute J 1993;20:28-32.